Sipuleucel-T immune parameters correlate with survival: An analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer

Cancer Immunology, Immunotherapy

Volumn 62, Issue 1, 2013, Pages 137-147

  Sheikh, Nadeem A ^a   Petrylak, Daniel ^b   Kantoff, Philip W ^c   Dela Rosa, Corazon ^a   Stewart, Frances P ^a   Kuan, Ling Yu ^a   Whitmore, James B ^a   Trager, James B ^a   Poehlein, Christian H ^a   Frohlich, Mark W ^a   Urdal, David L ^a  

^a Dendreon   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cellular; Humoral; Immunotherapy; Prostate cancer; Survival

Indexed keywords

CHEMOKINE; INTERCELLULAR ADHESION MOLECULE 1; SIPULEUCEL T;

ADULT; AGED; ANTIGEN PRESENTING CELL; ARTICLE; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; MOLECULAR DYNAMICS; MULTICENTER STUDY; MULTINUCLEAR CELL; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; UPREGULATION;

AGED; AGED, 80 AND OVER; ANTIGEN-PRESENTING CELLS; CHEMOKINES; DOUBLE-BLIND METHOD; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; ORCHIECTOMY; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; T-LYMPHOCYTES; TISSUE EXTRACTS;

EID: 84872488155     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-012-1317-2     Document Type: Article

References (36)

1. Drake CG (2010) Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol 10:580-593. doi: 10.1038/nri2817
2. Dudley ME, Wunderlich JR, Robbins PF et al (2002) Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298:850-854
3. Neelapu SS, Kwak LW, Kobrin CB et al (2005) Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. Nat Med 11:986-991. doi: 10.1038/nm1290
4. Slingluff CL Jr, Petroni GR, Olson WC et al (2009) Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial. Clin Cancer Res 15:7036-7044. doi: 10.1158/1078-0432.CCR-09- 1544
5. Goldstein NS (2002) Immunophenotypic characterization of 225 prostate adenocarcinomas with intermediate or high Gleason scores. Am J Clin Pathol 117:471-477
6. Haines AM, Larkin SE, Richardson AP, Stirling RW, Heyderman E (1989) A novel hybridoma antibody (PASE/4LJ) to human prostatic acid phosphatase suitable for immunohistochemistry. Br J Cancer 60:887-892
7. Chang DZ, Lomazow W, Joy Somberg C, Stan R, Perales MA (2004) Granulocyte-macrophage colony stimulating factor: an adjuvant for cancer vaccines. Hematology 9:207-215
8. Fleetwood AJ, Cook AD, Hamilton JA (2005) Functions of granulocyte-macrophage colony-stimulating factor. Crit Rev Immunol 25:405-428
9. Hadaschik B, Su Y, Huter E, Ge Y, Hohenfellner M, Beckhove P (2012) Antigen specific T-cell responses against tumor antigens are controlled by regulatory T cells in patients with prostate cancer. J Urol 187:1458-1465. doi: 10.1016/j.juro.2011.11.083
10. McNeel DG, Nguyen LD, Ellis WJ, Higano CS, Lange PH, Disis ML (2001) Naturally occurring prostate cancer antigen-specific T cell responses of a Th1 phenotype can be detected in patients with prostate cancer. Prostate 47:222-229. doi: 10.1002/pros.1066
11. McNeel DG, Nguyen LD, Storer BE, Vessella R, Lange PH, Disis ML (2000) Antibody immunity to prostate cancer associated antigens can be detected in the serum of patients with prostate cancer. J Urol 164:1825-1829
12. Becker JT, Olson BM, Johnson LE, Davies JG, Dunphy EJ, McNeel DG (2010) DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer. J Immunother 33:639-647. doi: 10.1097/CJI.0b013e3181dda23e
13. McNeel DG, Dunphy EJ, Davies JG et al (2009) Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J Clin Oncol 27:4047-4054. doi: 10.1200/JCO.2008.19. 9968
14. Kantoff PW, Higano CS, Shore ND et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411-422
15. Higano CS, Schellhammer PF, Small EJ, Burch PA, Nemunaitis J, Yuh L, Provost N, Frohlich MW (2009) Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 115:3670-3679. doi: 10.1002/cncr.24429
16. Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, Verjee SS, Jones LA, Hershberg RM (2006) Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 24:3089-3094
17. Burch PA, Breen JK, Buckner JC et al (2000) Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res 6:2175-2182
18. Sheikh NA, Jones LA (2008) CD54 is a surrogate marker of antigen presenting cell activation. Cancer Immunol Immunother 57:1381-1390. doi: 10.1007/s00262-008-0474-9
19. Corradin G, Etlinger HM, Chiller JM (1977) Lymphocyte specificity to protein antigens. I. Characterization of the antigen-induced in vitro T cell-dependent proliferative response with lymph node cells from primed mice. J Immunol 119:1048-1053
20. Armstrong AJ, Garrett-Mayer ES, Yang YC, de Wit R, Tannock IF, Eisenberger M (2007) A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res 13:6396-6403. doi: 10.1158/1078-0432.CCR-07-1036
21. Halabi S, Small EJ, Kantoff PW, Kattan MW, Kaplan EB, Dawson NA, Levine EG, Blumenstein BA, Vogelzang NJ (2003) Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 21:1232-1237
22. Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P (2005) Molecular biology of the cell, 4th edn. Garland Science, New York
23. Di Mascio M, Paik CH, Carrasquillo JA et al (2009) Noninvasive in vivo imaging of CD4 cells in simian-human immunodeficiency virus (SHIV)-infected nonhuman primates. Blood 114:328-337. doi: 10.1182/blood-2008-12-192203
24. Trepel F (1974) Number and distribution of lymphocytes in man. A critical analysis. Klin Wochenschr 52:511-515
25. Sprent J, Cho JH, Boyman O, Surh CD (2008) T cell homeostasis. Immunol Cell Biol 86:312-319. doi: 10.1038/icb.2008.12
26. Flanigan R, Price T, Whitmore J, Holman J (2011) Safety of leukapheresis in prostate cancer patients receiving sipuleucel-T. J Urol 185:e261 (Abstract 646)
27. Hall SJ, Klotz L, Pantuck AJ, George DJ, Whitmore JB, Frohlich MW, Sims RB (2011) Integrated safety data from 4 randomized, double-blind, controlled trials of autologous cellular immunotherapy with sipuleucel-T in patients with prostate cancer. J Urol 186:877-881
28. Beck G, Habicht GS, Benach JL, Miller F (1986) Interleukin 1: a common endogenous mediator of inflammation and the local Shwartzman reaction. J Immunol 136:3025-3031
29. Kirkham B (1991) Interleukin-1, immune activation pathways, and different mechanisms in osteoarthritis and rheumatoid arthritis. Ann Rheum Dis 50:395-400
30. Laus R, Yang DM, Ruegg CL, Shapero MH, Slagle PH, Small EJ, Burch PA, Valone FH (2001) Dendritic cell immunotherapy of prostate cancer: preclinical models and early clinical experience. Cancer Res Ther Control 11:1-10
31. Chang SH, Dong C (2007) A novel heterodimeric cytokine consisting of IL-17 and IL-17F regulates inflammatory responses. Cell Res 17:435-440. doi: 10.1038/cr.2007.35
32. Lohr J, Knoechel B, Wang JJ, Villarino AV, Abbas AK (2006) Role of IL-17 and regulatory T lymphocytes in a systemic autoimmune disease. J Exp Med 203:2785-2791. doi: 10.1084/jem.20061341
33. Willinger T, Freeman T, Hasegawa H, McMichael AJ, Callan MF (2005) Molecular signatures distinguish human central memory from effector memory CD8 T cell subsets. J Immunol 175:5895-5903
34. Small EJ, Fratesi P, Reese DM, Strang G, Laus R, Peshwa MV, Valone FH (2000) Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 18:3894-3903
35. Ai WZ, Tibshirani R, Taidi B, Czerwinski D, Levy R (2009) Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma. Blood 113:5743-5746. doi: 10.1182/blood-2009-01-201988
36. Fong L, Weinberg VK, Chan SE et al (2012) Neoadjuvant sipuleucel-T in localized prostate cancer: effects on immune cells within the prostate tumor microenvironment. J Clin Oncol 30: abstr 2564. http://www.asco.org/ASCOv2/ Meetings/Abstracts?&vmview=abst-detail-view&confID=114&abstractID= 94333